Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00407433 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Studies of Gemcitabine-Oxaliplatin

StatusCompleted
PhasePhase 2
View on ClinicalTrials.gov ↗

Record History

  1. Study Status, Sponsor/Collaborators, Referencesv5
  2. Trial status: Recruiting to Completed Site details revisedv4 Show 1 more changeShow less
    • Site details revised
  3. Eligibility criteria expanded, about 9 words Site contact updated · Study title shortened, about 2 wordsv3 Show 2 more changesShow less
    • Site contact updated
    • Study title shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Not Yet Recruiting to Recruiting Site details revisedv2 Show 1 more changeShow less
    • Site details revised
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
These are Phase 2 single-arm studies of gemcitabine in combination with oxaliplatin in refractory or relapsing pediatric solid tumors.
Trial Details
NCT Number NCT00407433
Lead Sponsor Gustave Roussy, Cancer Campus, Grand Paris
Conditions Medulloblastoma, Central Nervous System Tumors, Neuroblastoma, Osteosarcoma
Enrollment 156 participants
Updated on ClinicalTrials.gov